The influence of gender on the effects of aspirin in preventing myocardial infarction by Yerman, Todd et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Medicine
Open Access Research article
The influence of gender on the effects of aspirin in preventing 
myocardial infarction
Todd Yerman, Wen Q Gan and Don D Sin*
Address: Department of Medicine (Respiratory Division), University of British Columbia, and The James Hogg iCAPTURE Center for 
Cardiovascular and Pulmonary Research, St. Paul's Hospital, Vancouver, British Columbia, Canada
Email: Todd Yerman - todd.yerman@utoronto.ca; Wen Q Gan - wenqi@interchange.ubc.ca; Don D Sin* - dsin@mrl.ubc.ca
* Corresponding author    
Abstract
Background: There is considerable variation in the effect of aspirin therapy reducing the risk of
myocardial infarction (MI). Gender could be a potential explanatory factor for the variability. We
conducted a systematic review and meta-analysis to determine whether gender mix might play a
role in explaining the large variation of aspirin efficacy across primary and secondary MI prevention
trials.
Methods:  Randomized placebo-controlled clinical trials that examined the efficacy of aspirin
therapy on MI were identified by using the PUBMED database (1966 to October 2006). Weighted
linear regression technique was used to determine the relationship between log-transformed
relative risk (RR) of MI and the percentage of male participants in each trial. The reciprocal of the
standard error of the RR in each trial (1/SE) was used as the weight.
Results: A total of 23 trials (n = 113 494 participants) were identified. Overall, compared with
placebo, aspirin reduced the risk of non-fatal MI (RR = 0.72, 95% confidence interval (CI) 0.64–0.81,
p < 0.001) but not of fatal MI (RR = 0.88, 95% CI 0.75–1.03, p = 0.120). A total of 27% of the
variation in the non-fatal MI results could be accounted for by considering the gender mix of the
trials (p = 0.017). Trials that recruited predominantly men demonstrated the largest risk reduction
in non-fatal MI (RR = 0.62, 95% CI 0.54–0.71), while trials that contained predominately women
failed to demonstrate a significant risk reduction in non-fatal MI (RR = 0.87, 95% CI 0.71–1.06).
Conclusion: Gender accounts for a substantial proportion of the variability in the efficacy of
aspirin in reducing MI rates across these trials, and supports the notion that women might be less
responsive to aspirin than men.
Background
Although it is widely accepted that aspirin reduces the risk
of myocardial infarction (MI) on average by 25%, there is
considerable variation in the effect sizes reported across
the trials ranging from zero to 50% relative to placebo [1].
To date, factors responsible for this heterogeneity have
not been well studied. One potential explanatory variable
is gender. There is emerging evidence to indicate that
women have an increase risk of aspirin resistance com-
pared to men, potentially making aspirin less effective in
women [2]. Moreover, women who develop atherosclero-
sis tend to be older, have more co-morbid conditions and
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more extensive disease at the time of diagnosis, which
might also interfere with the actions of aspirin [2]. Thus,
the gender mix of published trials could be an important
determinant of the variability in the reported findings.
The primary purpose of this study was to determine the
influence of gender mix on the reported efficacy of aspirin
on fatal and non-fatal MI in published clinical trials.
Methods
Search for relevant studies
We conducted a comprehensive literature search by using
the PUBMED electronic database (1966 to October 2006)
to identify randomized placebo-controlled clinical trials
that examined the efficacy of aspirin therapy on myocar-
dial infarction (MI). We limited the search to randomized
controlled trials conducted in human subjects and pub-
lished in English language, using aspirin and MI-specific
search terms. We supplemented the electronic search by
probing the reference lists of retrieved articles and previ-
ous reviews on this topic, and by a search of the Anti-
thrombotic Trialists' Collaboration website [3] and
EMBASE. We also contacted primary authors where neces-
sary for clarification of data.
Study selection and data abstraction
The primary objective of this study was to determine the
impact of gender mix on the reported efficacy of aspirin
on MI rates. We excluded trials that: (1) had a follow-up
period of less than 3 months; (2) co-administered aspirin
with another agent; (3) prescribed aspirin for clinical indi-
cations other than for primary or secondary cardiovascu-
lar prevention (e.g. pain, headache, or arthritic
symptoms); (4) did not have a placebo arm; (5) had a
paucity of MI events (fewer than 10) during follow-up; or
(6) had unacceptable methodological quality score (Jadad
score of less than 3) [4]. From each retrieved article, two
independent investigators abstracted the following infor-
mation: project name, characteristics of participants, sam-
ple size, average age of the sample at baseline,
proportionality of current smokers and male participants,
duration of follow up, and dosage of aspirin (Table 1),
and calculated the relative risks (RR) and 95% confidence
intervals (CI) for fatal and non-fatal MI separately as well
as combined [5-27]. Any questions or discrepancies
regarding these data were resolved through iteration and
consensus.
Statistical analysis
We used both unweighted and weighted linear regression
techniques to determine the relationship between log-
transformed RR of MI and gender mix of the trial partici-
pants (i.e. the percentage of male or female subjects in
each trial). In the weighted analysis, we used the recipro-
cal of the standard error of the RR in each trial (1/SE) as
the weight. As the weighted and unweighted analysis pro-
duced similar results, we report on the weighted analysis
only unless otherwise indicated. All tests were two-tailed
in nature and were performed using SAS statistical soft-
ware (version 9.1, SAS Institute, Carey, NC, USA).
In a separate analysis, we divided the original trials into
tertile groups based on the percentage of male participants
included in each trial. We used a random effects model to
combine the results of the trials to take into account both
within as well as between trial variances [28]. Data analy-
ses were conducted using STATA statistical software
(STATA release 9, STATA Corporation, College Station,
Texas, USA) and Review Manager V. 4.2 (Revman The
Cochrane Collaboration, Oxford, UK).
Results
The original search in PUBMED yielded 637 citations.
EMBASE did not contribute any additional citations. The
abstracts of these articles were selected and reviewed. Of
these, 61 articles were retrieved for detailed examination.
From these, 23 trials were selected as they met the inclu-
sion and exclusion criteria of the study: 21 of these trials
reported on non-fatal MI, 15 trials reported on fatal MI,
and 17 reported on both fatal and non-fatal MI. The selec-
tion process is depicted in Figure 1. The baseline charac-
teristics of participants in the selected trials are
summarized in Table 1[5-27]. Overall, there were 113 494
participants in the 23 included trials; 49.3% were men.
The baseline mean age of the trial participants ranged
between 52 and 73 years; the prevalence of current smok-
ers varied from 11% to 60%. The duration of follow-up
was from 1–10 years and the dosage of aspirin varied from
75–1500 mg per day.
The main findings of the study are summarized in Table
2. Overall, aspirin significantly reduced the risk of non-
fatal MI compared with placebo (RR = 0.72, 95% CI 0.64–
0.81, p < 0.001) (Figure 2). There was a trend towards
lower fatal MI rates with aspirin (RR = 0.88, 95% CI 0.75–
1.03, p = 0.120) (Table 2). Aspirin therapy significantly
reduced the combined endpoint of fatal and non-fatal MI
(RR = 0.79, 95% CI 0.72–0.87, p < 0.001) (Table 2).
In a meta-regression analysis, we observed a significant
relationship between gender mix (i.e. proportionality of
male or female participants in each trial) and the effective-
ness of aspirin in reducing non-fatal MI rates in these trials
(R2 = 0.27, p = 0.017) (Figure 3). However, we failed to
observe a significant impact of gender mix on the effect
sizes for fatal MI (R2 = 0.03, p = 0.514). The relationship
between gender mix and the effectiveness of aspirin in
reducing the combined end point of fatal and non-fatal
MI was only marginally significant (R2 = 0.21, p = 0.065).
The inclusion of average age and smoking status of the
trial participants made very little impact to the overallB
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Table 1: Characteristics of selected trials
Author (year) Trial name Participants Sample
size
Mean age at 
baseline 
(year)
Current 
smoker (%)
Male (%) Follow-up 
(year)
Aspirin 
dose
 (mg/day)
Ridker et al [26] (2005) Women's Health Study (WHS) Healthy women ≥ 45 years in USA 39 876 55 13 0 10.0 100†
de Gaetano [19] (2001) Primary Prevention Project (PPP) Patients with at least one of the major recognized 
cardiovascular risk factors in Italy
4 495 64 15 42 3.6 100
Cote et al [18] (1995) Asymptomatic Cervical Bruit Study 
(ACBS)
Patients with asymptomatic carotid stenosis in 
Canada
372 67 37 45 2.3 325
ETDRS Study Group [13] (1992) Early Treatment Diabetic Retinopathy 
Study report (ETDRS)
Patients with a clinical diagnosis of diabetes 
mellitus
3 711 18–70 44# 52 5.0 650
Juul-Moller et al [24] (1992) Swedish Angina Pectoris Aspirin Trial 
(SAPAT)
Patients with chronic stable angina 2 035 67 16 52 4.2 75
Hansson et al [23] (1998) Hypertension Optimal Treatment 
Study (HOT)
Patients with hypertension and diastolic blood 
pressure between 100 mmHg and 115 mmHg 
from countries in Europe, America, and Asia
18 790 62 16 53 3.8 75
Swedish cooperative [8] (1987) Swedish Cooperative Study (Swedish 
Coop)
Patients with cerebral infarction, minor or major 
stroke
505 68 52 62 2.0 1 500
EAFT Study Group [14] (1993) European Atrial Fibrillation Trial 
(EAFT)
Patients with non-rheumatic atrial fibrillation 782* 73 19 63 2.3 300
SALT Collaborative Group [11] 
(1991)
Swedish Aspirin Low-Dose Trial 
(SALT)
Patients after transient ischaemic attack (TIA) or 
minor stroke
1 360 67 25 66 2.7 75
Cairns et al [17] (1985) Canadian multicenter trial (Canadian) Patients with unstable angina who were 
hospitalized in coronary care units in Canada
278* 57 35 70 1.5 1 300
Stroke Prevention in Atrial 
Fibrillation Study group [12] (1991)
Stroke Prevention in Atrial Fibrillation 
Study (SPAF)
Patients with constant or intermittent atrial 
fibrillation
1 120* 67 16 71 1.3 325
Sorensen et al [27] (1983) A Danish cooperative study (Danish 
Coop)
Patients experienced at least one reversible 
cerebral ischemic attack
203 59 24¶ 73 2.0 1 000
Farrell et al [22] (1991) United Kingdom transient ischaemic 
attack aspirin trial (UK-TIA)
Patients with a transient ischaemic attack or 
minor ischaemic stroke
2 435 60 53 73 4.0 300/1 200
Persantine-Aspirin Reinfarction Study 
Research Group [5] (1980)
Persantine-aspirin Reinfarction Study 
(PARIS)
Patients recovered from myocardial infarction 1 216* 56 27 77 3.4 972
Breddin et al [16] (1980) German-Austrian aspirin trial (GAAT) Patients who had survived a myocardial infarction 
for 30–42 days
626 45–70 58 78 2.0 1 500
Elwood and Sweetnam [21] (1979) Aspirin and secondary mortality after 
myocardial infarction (Cardiff-II)
Patients with confirmed myocardial infarction 1 725‡ 56 60 85 1.0 900
AMIS Study Group [6] (1980) Aspirin myocardial infarction study 
(AMIS)
Patients experienced at least one myocardial 
infarction in USA
4 524 55 27 89 3.0 1 000
Elwood et al [20] (1974) Secondary prevention of mortality 
from myocardial infarction (Cardiff-I)
Patients with recent myocardial infarction 1 239‡ 55 NA 100 1.1 300
Coronary Drug Project Research 
Group [7] (1980)
Coronary Drug Project Aspirin Study 
(CDPA)
Patients with a history of myocardial infarction 1 529‡ NA NA 100 1.8 324
Lewis et al [25] (1983) Veterans Administration Cooperative 
Study (VACS)
Patients with unstable angina in USA 1 266 56 50 100 1.0 324
Steering Committee of the 
Physicians' Health Study Research 
Group [9] (1989)
Physicians' Health Study (PHS) Healthy male physicians in USA 22 071 52 11 100 5.0 325†
The RISC Group [10] (1990) Research Group on Instability in 
Coronary Artery Disease (RISC)
Men with unstable coronary artery disease in 
Southeast Sweden
796* 58 38 100 1.0 75
Medical Research Council's General 
Practice Research Framework Group 
[15] (1998)
Thrombosis prevention Trial (TPT) Patients at high risk of cardiovascular disease in 
UK
2 540 58 41 100 4.0 75
NA: not available.
*Only the participants in placebo group and aspirin group were included.
† Every other day.
‡ Data are from [4].
¶ > 15 cigarettes/day.
# ≥ 6 cigarettes/day.BMC Medicine 2007, 5:29 http://www.biomedcentral.com/1741-7015/5/29
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findings. For the end point of non-fatal MI, the R2 value
was 0.32 (p = 0.038). For fatal MI, it was 0.09 (p = 0.465)
and for the combined end point of fatal and non-fatal MI,
it was 0.28 (p = 0.072).
When the original trials were divided into tertile groups
based on the gender mix (0–66%, 70–89%, 100% male
participants in each trial), the beneficial effect of aspirin in
reducing non-fatal MI was found to be the greatest in the
tertile group containing the largest percentage of male
participants (RR = 0.62, 95% CI 0.54–0.71), test for heter-
ogeneity, p = 0.48). In contrast, the tertile group with the
smallest percentage of male participants failed to demon-
strate any benefits of aspirin in reducing non-fatal MI (RR
= 0.87, 95% CI 0.71–1.06), test for heterogeneity, p =
0.26) (Table 3). Similar findings were observed in the
analysis that combined non-fatal and fatal MI together
(Table 3).
Discussion
The findings of the present study indicate that aspirin is
effective in reducing the risk for non-fatal MI. There was
however considerable variation in the reported efficacy of
aspirin across the trials. We found that approximately
27% of the total variation could be accounted for by con-
sidering the differences in the gender mix of the trials. In
general, the trials that contained predominantly male sub-
Table 2: Relative risks and 95% confidence intervals of myocardial infarction in each trial
Source Male (%) Non–fatal MI Fatal MI Fatal and non-fatal MI
WHS [26] (2005) 0 1.02 (0.83–1.25) 1.17 (0.54–2.52) 1.03 (0.84–1.25)
PPP [19] (2001) 42 0.69 (0.36–1.34) 0.68 (0.19–2.40) 0.69 (0.39–1.23)
ACBS [18] (1995) 45 1.71 (0.51–5.75) NA NA
ETDRS [13] (1992) 52 NA NA 0.85(0.73–1.00)
SAPAT [24] (1992) 52 0.61 (0.43–0.87) 1.02 (0.50–2.07) 0.68 (0.50–0.92)
HOT [23] (1998) 53 NA NA 0.85 (0.69–1.05)
Swedish cooperative [8] (1987) 62 0.88 (0.45–1.72) 1.00 (0.33– 3.05) 0.91 (0.52, 1.60)
EAFT [14] (1993) 63 0.94 (0.35–2.47) 0.90 (0.52–1.56) 0.91 (0.56–1.46)
SALT [11] (1991) 66 0.91 (0.59–1.41) 0.65 (0.36–1.16) 0.80 (0.57–1.13)
Canadian group study [17] (1985) 70 1.29 (0.49–3.36) 0.54 (0.22–1.31) 0.80 (0.43–1.48)
SPAF [12] (1991) 71 0.57 (0.19–1.70) NA NA
Danish cooperative [27] (1983) 73 0.25 (0.05–1.16) 0.67 (0.20–2.31) 0.43 (0.17–1.08)
UK–TIA [22] (1991) 73 0.86 (0.68–1.11) 1.01 (0.74–1.39) 0.92 (0.77–1.11)
PARIS [5] (1980) 77 0.68 (0.47–1.01) 0.79 (0.55–1.15) 0.74 (0.57–0.95)
GAAT [16] (1980) 78 0.63 (0.39–1.03) 0.58 (0.30–1.12) 0.61 (0.42–0.89)
Cardiff–II [21] (1979) 85 0.49 (0.33–0.75) NA NA
AMIS [6] (1980) 89 0.78 (0.63–0.96) 1.08 (0.89–1.31) 0.93 (0.81–1.07)
Cardiff–I [20] (1974) 100 0.68 (0.31–1.49) NA NA
CDPA [7] (1980) 100 0.86 (0.52–1.42) NA NA
VACS [25] (1983) 100 0.49 (0.29–0.81) 0.17 (0.02–1.42) 0.45 (0.28–0.74)
PHS [9] (1989) 100 0.61 (0.49–0.75) 0.38 (0.19–0.80) 0.58 (0.47–0.72)
RISC [10] (1990) 100 0.49 (0.33–0.73) NA NA
TPT [15] (1998) 100 0.68 (0.53–0.89) 1.13 (0.78–1.63) 0.81 (0.66–0.99)
Total 49 0.72 (0.64–0.81) 0.88 (0.75–1.03) 0.79 (0.72–0.87)
MI, myocardial infarction; NA, not available.
Flow diagram of study selection Figure 1
Flow diagram of study selection. MI, myocardial infarc-
tion.
Same cohort reports: n=21
Total MI events less than 10: n=8
No placebo control: n=4
Duration less than 3 month: n=3
No sufficient data: n=2
Did not meet criteria or 
duplicate articles: n=612
Studies retrieved: n=61
Studies identified: N=23
Non-fatal MI: n=21
Fatal MI: n=15
Non-fatal and fatal MI: n=17
Search results: N=673
PUBMED: n=673BMC Medicine 2007, 5:29 http://www.biomedcentral.com/1741-7015/5/29
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jects demonstrated large benefits of aspirin in reducing
non-fatal MI rates. In contrast, trials that contained mostly
female subjects failed to show any beneficial effect of aspi-
rin on this end point. These data are consistent with the
notion that aspirin therapy might be less effective in
reducing non-fatal MI in women than in men.
Why aspirin would be less effective in reducing MI risk in
women is largely a mystery. However, recent data indicate
that women are more likely to demonstrate aspirin resist-
ance compared to men. In a study by Chen and col-
leagues, women compared to men were 2.3 times more
likely to be aspirin-resistant [29] and in the study by Gum
and colleagues, women were 2.5 times more likely to
demonstrate aspirin resistance [2]. The mechanisms
underlying these observations are uncertain.
There are also emerging data demonstrating major struc-
tural and physiological differences in coronary vascula-
ture between men and women [30]. For instance, women
have smaller coronary vessels, which are generally stiffer
than those in men owing to increased deposition of
fibrotic tissue and remodeling of the vessel walls. Women
are also more likely to demonstrate impaired vasodilatory
responses to acetylcholine [31]. Moreover, when women
develop atherosclerosis, their lesions are usually more dif-
fuse and extensive than those observed in men [32].
Although in both men and women, the leading cause of
morbidity and mortality is ischemic heart disease [33],
women, especially in the younger age groups (less than 50
years of age), have short-term mortality rates that are twice
those observed in men following MIs [34]. Our findings
in the context of the emerging literature regarding possi-
ble aspirin resistance in women suggest that clinicians
should be cautious in prescribing aspirin in women espe-
cially for primary prevention. Whether or not other anti-
platelet agents would be more effective for women is
unclear. Future clinical studies specifically powered to
The impact of gender mix on the reported efficacy of aspirin  in reducing non-fatal myocardial infarction risk Figure 3
The impact of gender mix on the reported efficacy of 
aspirin in reducing non-fatal myocardial infarction 
risk. The regression line is weighted by the reciprocal of the 
standard error (1/SE) of the relative risk of each trial. The 
diameter of each circle is proportional to 1/SE of each trial.
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Table 3: Relative risks and 95% confidence intervals of myocardial infarction stratified by percentage of male participants
Male (%) Non-fatal MI p* Fatal MI p* Both fatal and non-fatal MI p*
0–66 0.87 (0.71–1.06) 0.26 0.87 (0.65–1.17) 0.86 0.86 (0.79–0.95) 0.52
70–89 0.72 (0.61–0.86) 0.23 0.91 (0.75–1.11) 0.24 0.82 (0.71–0.95) 0.13
100 0.62 (0.54–0.71) 0.48 0.55 (0.20–1.53) 0.01 0.63 (0.46–0.85) 0.02
Total 0.72 (0.64–0.81) 0.03 0.88 (0.75–1.03) 0.19 0.79 (0.72–0.87) < 0.05
MI, myocardial infarction.
*Test for heterogeneity, p value is from χ2 test. Ransom effects model was used in all combinations.
The effect of aspirin on the risk for non-fatal myocardial inf- arction (MI) compared with placebo Figure 2
The effect of aspirin on the risk for non-fatal myocardial inf-
arction (MI) compared with placebo.
.1 .2 .5 1 2 5
0.72 (0.64,0.81)
WHS2005
PPP2001
ACBS1995
SAPAT1992
Swedish1987
EAFT1993
SALT1991
Cairns1985
SPAFS1991
Danish1983
UK-TIA1991
PARIS1980
GAAT1980
Cardiff-II1979
AMIS1980
Cardiff-I1974
CDPA1980
PHS1989
RISC1990
TPT1998
VACS1985
Overall (95% CI)
Relative Risk for Non-Fatal MI BMC Medicine 2007, 5:29 http://www.biomedcentral.com/1741-7015/5/29
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evaluate sex-specific end points will be needed to deter-
mine whether other anti-platelet agents might be more
effective in women compared with aspirin.
There were limitations to the present study. Firstly, we did
not have access to the primary data. As such, we could not
determine the influence of other risk factors such as co-
morbidities that have also been associated with aspirin-
resistance [35]. These factors could further explain the
large variation in results reported across the trials. Sec-
ondly, as with most systematic reviews, there was a possi-
bility of publication or selection bias. To mitigate this
possibility, we conducted an extensive search and
included all trials that met the inclusion and exclusion cri-
teria of the present study. Thirdly, we could not determine
the mechanism by which gender modifies the efficacy of
aspirin for MIs.
Conclusion
The present study found that the gender mix of trials
accounted for a substantial proportion of the variability in
the reported efficacy of aspirin in reducing MI rates. Trials
that recruited predominantly men demonstrated the larg-
est benefits; while trials that recruited mostly women
failed to demonstrate any benefits. These data are consist-
ent with the notion that aspirin is less efficacious in
women (for the reduction of MIs) and raise the possibility
that women are more susceptible to aspirin resistance.
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